Skip to main content
TTrialFinderData
TrialFinderData is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Updated May 2026 · ClinicalTrials.gov

Icahn School of Medicine at Mount Sinai

19 clinical trials · 19 recruiting · OTHER

Icahn School of Medicine at Mount Sinai has 19 clinical trials registered on ClinicalTrials.gov, with 19 actively recruiting participants. The trials listed below cover 20 conditions across the phases listed in the sidebar. Always discuss any specific trial with your physician before contacting a study site.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About Icahn School of Medicine at Mount Sinai\'s Trial Portfolio

Icahn School of Medicine at Mount Sinai is a non-industry sponsor (academic medical center, hospital, foundation, or research network). Non-industry sponsors often investigate novel approaches, rare conditions, and behavioral or surgical interventions that commercial sponsors may not prioritize.

19 of Icahn School of Medicine at Mount Sinai's 19 registered trials are currently recruiting — roughly 100% of the portfolio. A high recruiting share usually points to an active research pipeline with multiple programs at the enrollment stage.

Icahn School of Medicine at Mount Sinai's research footprint spans Long COVID (2 trials), Prostate Cancer (1), and elevated-psa (1) as the top three conditions. The full condition list, sorted by trial count, is in the sidebar.

Not Applicable is the largest single phase in Icahn School of Medicine at Mount Sinai's portfolio at 37% of registered trials. The full phase breakdown appears in the sidebar.

Trials by Icahn School of Medicine at Mount Sinai

RECRUITINGNCT03474913

Upright MRI for Prostate Cancer Screening

This is an investigator initiated study to test the efficacy of an upright MRI (Magnetic Resonance Imaging) for the screening of prostate cancer. The purpose of this study is to...

Sponsor: Icahn School of Medicine at Mount SinaiEnrolling: 5501 location
Prostate CancerElevated PSAElevated Prostate Specific Antigen
RECRUITINGPhase 2NCT05462496

Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer

A multi-institutional, single arm pilot study of antibiotics and pembrolizumab, following chemotherapy for the treatment of surgically resectable pancreatic cancer.

Sponsor: Icahn School of Medicine at Mount SinaiEnrolling: 251 location
Pancreatic Cancer
RECRUITINGNCT06689176

Chlorhexidine Antiseptic Irrigation of the Bowel Segment During Radical Cystectomy and Urinary Diversion

This is a single arm, interventional pilot study of using chlorhexidine irrigation intra-operatively and post-operatively among patients undergoing radical cystectomy with urinary...

Sponsor: Icahn School of Medicine at Mount SinaiEnrolling: 231 location
Bladder CancerUrinary Tract Infection
RECRUITINGNCT05172921

Environmental Factors and Thyroid Cancer

Thyroid cancer incidence has been steadily increasing and has nearly tripled since the 1970's in the US and worldwide. Early detection of small, papillary thyroid cancers using...

Sponsor: Icahn School of Medicine at Mount SinaiEnrolling: 5001 location
Thyroid Cancer
RECRUITINGNCT04615988

Correlation Vitamin D Level to Endocrine Autoimmune Toxicity Due to Immune Checkpoint Inhibitors

The purpose of this research study is to see if the amount of vitamin D in ones blood makes it more or less likely to develop thyroid gland toxicity when being treated with...

Sponsor: Icahn School of Medicine at Mount SinaiEnrolling: 171 location
ThyroidPD-1Cancer
RECRUITINGPhase 3NCT04045665

Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG

The primary objective of this study is to evaluate the effectiveness (prevention of thromboembolic events) and safety (major bleeding) of adding oral anticoagulation (OAC) to...

Sponsor: Icahn School of Medicine at Mount SinaiEnrolling: 320020 locations
Atrial FibrillationStrokeBleeding
RECRUITINGPhase 2NCT07493317

Neutralizing Interleukin (IL)-6

The proposed study aims to establish the feasibility and safety of subcutaneous tocilizumab, a monoclonal antibody (mAb) against interleukin (IL)-6 receptor, in adults with Major...

Sponsor: Icahn School of Medicine at Mount SinaiEnrolling: 601 location
Major Depressive Disorder
RECRUITINGNCT07011901

Precision Analytic Research Methods in OCD

Psychiatric disorders characterized by compulsivity, such as obsessive-compulsive disorder (OCD), result in considerable functional impairment and many individuals do not respond...

Sponsor: Icahn School of Medicine at Mount SinaiEnrolling: 1001 location
Obsessive Compulsive Disorder
RECRUITINGNCT05160129

Connectomic Deep Brain Stimulation for Obsessive Compulsive Disorder

Deep brain stimulation (DBS) is an effective treatment for people suffering from severe obsessive-compulsive disorder (OCD) whose symptoms have failed to improve after years and...

Sponsor: Icahn School of Medicine at Mount SinaiEnrolling: 201 location
Obsessive Compulsive Disorder (OCD)
RECRUITINGPhase 4NCT03781765

Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk

The study team will examine the effects of FDA approved stimulant and non-stimulant medications for ADHD, among youth with ADHD and with and without Oppositional Defiant Disorder...

Sponsor: Icahn School of Medicine at Mount SinaiEnrolling: 441 location
ADHDAttention Deficit Hyperactivity Disorder
RECRUITINGNCT05554172

Efficacy of Non-invasive Vagus Nerve Stimulation for Treatment of Low Weight Eating Disorders

This project includes a 4-week randomized trial comparing pre-meal vagal nerve stimulation (taVNS) to pre-meal sham stimulation. The aims will assess if taVNS results in greater...

Sponsor: Icahn School of Medicine at Mount SinaiEnrolling: 301 location
Anorexia Nervosa
RECRUITINGNCT05562258

Development and Testing of a Peer-Coaching Model for the Treatment of Eating Disorders

This project includes developing and testing a coaching approach during the treatment of eating disorders. It is expected that with the addition of support outside of regular...

Sponsor: Icahn School of Medicine at Mount SinaiEnrolling: 701 location
Eating Disorder
RECRUITINGNCT03718936

ADNP Syndrome: The Seaver Autism Center for Research and Treatment is Characterizing ADNP-related Neurodevelopmental...

ADNP, also known as Activity Dependent Neuroprotective Protein, is a rare neurodevelopmental disorder caused by mutations encompassing the ADNP gene on chromosome 20. Clinically,...

Sponsor: Icahn School of Medicine at Mount SinaiEnrolling: 301 location
ADNPHelsmoortel-Van Der Aa SyndromeAutism Spectrum Disorder
RECRUITINGNCT06512597

Behavioral Therapy for Crohn's Disease

People living with Crohn's disease (CD) experience psychological and emotional symptoms, in addition to known chronic and disabling physical symptoms, which prevent them from...

Sponsor: Icahn School of Medicine at Mount SinaiEnrolling: 1702 locations
Crohn's Disease
RECRUITINGNCT06612294

Asthma Symptom Perception Study

Asthma affects 8% of the United States population ages \>60 years and causes considerable harm: older adults are 4 times more likely to die from asthma and have twice the risk of...

Sponsor: Icahn School of Medicine at Mount SinaiEnrolling: 3002 locations
Asthma
RECRUITINGPhase 3NCT06960928

Low Dose Sirolimus in People With Post-Acute Sequelae of COVID-19 (PASC) Long COVID-19

The study is conducted in New York, New York at The Cohen Center for Recovery from Complex Chronic Illness at Mount Sinai. This is an IND-exempt, off-label, multi-ascending,...

Sponsor: Icahn School of Medicine at Mount SinaiEnrolling: 801 location
Long COVID-19
RECRUITINGPhase 1 / Phase 2NCT06511050

Lumbrokinase for Adults With Long Covid, Post-treatment Lyme Disease Syndrome, and Myalgic Encephalomyelitis/Chronic...

This will be a pilot multi-arm clinical trial investigating the feasibility of Lumbrokinase (LK) as an intervention in three clinical cohorts: * Long Covid (LC) * Post-treatment...

Sponsor: Icahn School of Medicine at Mount SinaiEnrolling: 1201 location
Long CovidPost-treatment Lyme Disease SyndromeChronic Fatigue Syndrome+1
RECRUITINGPhase 2NCT06511063

Antiviral Clinical Trial for Long Covid-19

The trial will test if two repurposed HIV antivirals can reduce symptom burden in adult participants with Long Covid compared to placebo. Viral infection and viral reactivation...

Sponsor: Icahn School of Medicine at Mount SinaiEnrolling: 901 location
Long Covid
RECRUITINGPhase 1 / Phase 2NCT06930703

Cannabidiol in Sickle Cell Disease

Randomized, placebo-controlled, double masked, dose finding study of twice daily cannabidiol given at 3 dose levels, 200mg, 400mg, and 600mg, compared to placebo for 4 weeks.

Sponsor: Icahn School of Medicine at Mount SinaiEnrolling: 521 location
Sickle Cell Disease

How to Approach a Trial Listing

Each trial card above links to a dedicated page with the official ClinicalTrials.gov data plus a plain-English translation of the eligibility criteria. We translate technical terminology (ECOG performance status, hepatic function values, exclusionary lab thresholds) into language that a patient or caregiver can understand, but the original clinical text and the live ClinicalTrials.gov record always govern any actual eligibility decision.

Before contacting a trial site, write down questions for your treating physician using the framework on our 25 Questions guide. Discuss whether the trial fits your treatment plan, what the time commitment looks like, and whether your insurance will cover the standard-of-care portions. Trials are not a substitute for a treatment plan — they are an addition that needs medical guidance to evaluate.

Authoritative Resources

Verify any trial registration directly on ClinicalTrials.gov. For background on the FDA approval pathway that Phase 3 trials feed into, see the FDA drug approval process. For cancer-specific trial guidance, the National Cancer Institute publishes patient-oriented overviews. For global trial registrations beyond the U.S., the WHO ICTRP aggregates registries from around the world.

Frequently Asked Questions

How many clinical trials does Icahn School of Medicine at Mount Sinai have on ClinicalTrials.gov?

Icahn School of Medicine at Mount Sinai has 19 clinical trials registered on the federal ClinicalTrials.gov registry, of which 19 are actively recruiting participants right now. These counts come directly from the ClinicalTrials.gov API and are updated as the registry changes.

What conditions does Icahn School of Medicine at Mount Sinai study?

Icahn School of Medicine at Mount Sinai's registered trials cover 20 conditions on ClinicalTrials.gov, led by Long COVID (2 trials), Prostate Cancer (1 trial), elevated-psa (1 trial), elevated-prostate-specific-antigen (1 trial), Pancreatic Cancer (1 trial). The complete condition list appears in the sidebar of this page; each condition links to a page listing every recruiting trial in that area, regardless of sponsor.

How do I join a Icahn School of Medicine at Mount Sinai clinical trial?

Joining a clinical trial is a medical decision that should always involve your treating physician. Each trial page on this site includes the eligibility criteria translated into plain English alongside the official clinical text, plus the contact information that the sponsor has registered with ClinicalTrials.gov. Bring the trial information to your doctor before reaching out — they can review the full inclusion and exclusion criteria against your medical history and help you decide whether to pursue screening.

What does the trial phase mean?

Phase 1 trials test safety and dosing in small groups (often 20–80 healthy volunteers or patients). Phase 2 trials evaluate efficacy and side effects in larger groups (100–300 patients with the target condition). Phase 3 trials confirm efficacy and monitor safety in the largest groups (300–3,000+ patients) and form the basis of an FDA approval submission. Phase 4 studies happen after a treatment is approved, monitoring long-term safety and effectiveness in real-world use. Some trials register without a phase — common for device, behavioral, or observational studies.

Where does this trial data come from?

All trial data is pulled directly from the ClinicalTrials.gov API v2, the official federal trial registry maintained by the National Library of Medicine at NIH. Under FDAAA 801, most U.S. drug and device trials are required to register, making ClinicalTrials.gov the most comprehensive source. Sponsors are responsible for keeping their listings current; trial status can shift between data refreshes.

How This Sponsor Page Is Built

Every count on this page is derived directly from ClinicalTrials.gov API v2 records. Trial counts include all trials currently registered to this sponsor; the recruiting count reflects trials with status "Recruiting" or equivalent. Plain-English eligibility translations on each linked trial page preserve the original clinical text alongside an accessible version. Read the full methodology for the data pipeline and limitations.

Source: ClinicalTrials.gov API v2, maintained by the National Library of Medicine at NIH. Public domain. Cite as: "TrialFinderData. Data: ClinicalTrials.gov."

Medical disclaimer: This page is informational, not medical advice. Talk to your doctor about whether a clinical trial is right for you.

Last updated 2026-05-08 · 19 trials tracked for Icahn School of Medicine at Mount Sinai.

this entity is one of the data points covered by this site’s U.S. clinical trials and research registries dataset. The detail above comes directly from the NIH ClinicalTrials.gov registry; the context that follows situates the headline numbers against the broader distribution across active and historical clinical trials.

The methodology behind every numeric value on this page is publicly documented on the the NIH ClinicalTrials.gov registry portal and described in detail on this site’s methodology page. Refresh cadence varies by underlying series; the page surfaces the as-of date for each number so readers can trace any figure back to the source release.

For readers using this page as a decision input, the related-entity pages elsewhere on the site provide the comparison set. The most useful comparison for this entity is typically a peer within active and historical clinical trials with similar size, similar exposure, or similar geography — not the national-level summary alone.